By mike.scialom@iliffemedia.co.uk (Mike Scialom) STORM Therapeutics has closed its $30m Series B financing round, with proceeds set to expand STORM’s novel discovery platform. The pipeline is exemplified by STORM’s METTL3 inhibitor, STC-15, which has received IND (investigational new drug) application approval from the FDA and commenced its Phase 1 clinical study in cancer patients last month. STC-15 is an oral small molecule that inhibits METTL3 – an RNA methyltransferase implicated in oncology and other diseases. STORM presented preclinical data at the 34th EORTC-NCI-AACR and SITC meetings i…